Articles tagged with Biopsies
A new surgical platform using mass spectrometry identifies key gene mutations in brain cancer, including IDH mutations, during surgery. This allows for rapid diagnosis, prognosis, and tumor resection to improve patient outcomes.
Researchers at The Hebrew University have developed a novel method combining nano informatics and machine learning to predict cancer cell behaviors with high accuracy. This innovative approach enables the rapid identification of cancer cell subpopulations with varying biological behaviors, facilitating personalized medicine.
Researchers found low rates of metastasis and lymph node involvement in post-menopausal patients with early-stage ER+ breast cancer. This suggests that clinical guidelines for de-escalating surgery may be safely extended to younger patients.
Researchers have developed a method to use intense ultrasound to extract genetic information from cells, allowing for the detection of cancer biomarkers in blood samples. This approach could enable earlier detection and treatment of cancer, as well as reduce the need for painful biopsies.
Researchers have developed a new method to detect malignant melanoma using a microneedle patch that measures tyrosinase enzyme levels in the skin. This non-invasive technique has the potential to provide faster and more reliable results compared to traditional biopsies.
A team of researchers at Bar-Ilan University has developed a groundbreaking technology that enables direct measurement of the interaction between immune cells and cancer cells from a patient's biopsy. This innovation provides crucial insights into the patient's immune response, enabling tailored cancer treatment decisions.
Researchers created a proteomics-based imaging mass cytometry marker panel to categorize immune cells at single-cell resolution, identifying unique signatures of active T-cell-mediated rejection. The study aims to find personalized immunosuppression therapies with fewer side effects.
A new study found that PET/MRI can accurately classify prostate cancer patients and help avoid unnecessary biopsies. The PRIMARY scoring system showed that over 80% of unnecessary biopsies could be avoided while missing only 12.5% of clinically significant prostate cancer cases.
Researchers developed an AI algorithm to identify normal mammograms and ran a simulation on patient data, revealing that AI can reduce unnecessary testing while maintaining cancer detection rates. The study suggests that AI can help doctors focus on more questionable scans, reducing false positives and improving workflows.
Stanford researchers develop non-invasive 'virtual biopsy' using lasers and AI to create cell-by-cell reconstructions of skin or other tissue. The method mimics standard biopsies but provides rapid results and more information.
A novel exosome-based liquid biopsy approach has been developed to detect pancreatic cancer at early stages. The method combines eight microRNAs uniquely found in exosomes shed from pancreatic cancers with five cell-free DNA markers, achieving a 97% detection rate for stage 1-2 cases.
Integrating magnetic resonance imaging (MRI) in prostate cancer screening pathways is associated with reduced unnecessary biopsies and overdiagnosis. MRI maintains clinically significant prostate cancer detection, reducing harm from overtreatment.
Researchers found that doctors can confidently skip 50% of biopsies by combining MRI-based prostate imaging reporting and data system scores with prostate-specific antigen density testing. The study suggests that this approach can decrease patient harm and healthcare costs associated with unnecessary biopsies.
New data suggest that blood-based colorectal cancer screening tests could lead to more cases and deaths than established methods, despite improving outcomes for unscreened individuals. The tests are predicted to be less effective and more costly, making them unsuitable replacements for current screening programs.
Researchers developed a machine-learning model to assess prostate cancer biopsy samples, overcoming limitations of traditional methods. The new model, nnU-Net, provides accurate 3D segmentation of glandular tissue structures, leading to better prognostic analyses and potential improvements in patient outcomes.
Researchers developed a novel machine learning-based approach to analyze diffuse reflectance spectroscopy data, achieving higher accuracies and speeds than existing methods. The 'wavelength-independent regressor' model overcomes use-error limitations by incorporating diverse datasets, making it suitable for clinical settings.
A new study from MIT researchers found that doctors are less accurate in diagnosing skin diseases based on images of patients with darker skin. The researchers also discovered that an artificial intelligence algorithm can assist doctors in improving their diagnosis, although the improvements were more pronounced for lighter skin tones.
Liquid biopsies have the potential to monitor therapy success and predict tumor recurrence in high-risk neuroblastoma patients. The MONALISA project aims to establish liquid biopsies as a standard procedure for monitoring relapsed neuroblastoma, offering hope for improved personalized medicine.
A recent study published in the Journal of Clinical Gastroenterology found that liver biopsy was essential to making the correct diagnosis in over a third of cases. Biopsy was particularly valuable in diagnosing autoimmune hepatitis and was also used to diagnose liver fibrosis more than two-thirds of the time.
A new study by Northwestern University found that lab-trained AI models are easily misled by tissue contaminants, resulting in errors in diagnoses and vessel damage detection. The researchers suggest improving the problem of quantifying and addressing biological impurities in AI models to enhance accuracy.
Researchers found decreased BMAd density and altered distribution profile in MGUS patients who developed MM, indicating early changes in bone marrow adipose tissue. These findings suggest the potential for timely interventions and personalized treatment strategies.
A team of researchers from MIT and the Broad Institute developed two types of injectable molecules called 'priming agents' that can boost DNA levels in blood samples, allowing for earlier cancer diagnosis and more sensitive detection of tumor mutations. The approach could also help improve detection of cancer recurrence.
A new diagnostic kit allows dentists to screen for oral squamous cell carcinoma with a simple brush biopsy, detecting genetic signals of the disease with over 90% accuracy. The non-invasive test is less complicated than surgical biopsies and can be performed in under a minute without numbing required.
Researchers studied the effects of resveratrol on circadian clock gene expression in young and older human adipose-derived progenitor cells. They found increased levels of some components in older-APCs compared to young-APCs, but also observed gained rhythmicity of some components after resveratrol treatment.
Researchers at Johns Hopkins Medicine have identified six protein markers that can predict and manage acute kidney injury (AKI), a condition marked by serious inflammation. The study's findings offer hope for non-invasive assessments of AKI, potentially reducing the need for invasive kidney biopsies.
Researchers at Johns Hopkins Medicine used liquid biopsies to monitor changes in circulating tumor DNA and detect immune cell expansions, predicting patient responses to immunotherapies and detecting early signs of toxic side effects. The test showed significant associations with progression-free and overall survival.
A new study finds that analyzing surgical lymphatic fluid for HPV DNA can predict cancer recurrence and guide treatment decisions. The test was found to be more sensitive than traditional methods, detecting high-risk patients who may be missed by standard tools.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Researchers at the University of Leicester have received a significant financial boost to advance their cancer treatment research. The team will investigate 'liquid biopsies' to reveal vital clues about cancer genetic makeup, aiming to predict how cancer changes and which treatment works best for individual patients.
Researchers used spatial transcriptomics to analyze cancer cells at the edge and center of tumors, finding distinct gene expression patterns that can predict clinical outcomes and response to therapy. These findings hold promise for improving treatment strategies across various cancer types.
A team of University of Waterloo researchers has developed bio-compatible and non-toxic hydrogel composites using sustainable cellulose nanoparticles derived from plants. The tiny robots have the potential to conduct medical procedures, such as biopsy, and cell and tissue transport in a minimally invasive fashion.
A team of researchers has created a 'proteomic clock' that can predict a healthy person's age based on their protein profile, revealing accelerated aging due to diseases. The study also detected proteins associated with Parkinson's disease in eye fluid, offering a potential pathway for earlier diagnoses.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
A novel liquid biopsy test identifies levels of circulating tumor DNA as a more precise measure of disease burden than the number of tumors themselves. Patients with lower levels of detectable ctDNA are more likely to benefit from radiation therapy.
Two liquid biopsy tests identified patients with a high risk of cervical cancer recurrence after chemoradiation treatment, allowing for earlier detection and potential improvement in outcomes. The tests detected HPV ctDNA in the blood of patients with residual disease, providing insight before tissue biopsy becomes possible.
Researchers have developed a noninvasive brain biopsy technique using ultrasound and microbubbles to access brain tissue without surgery. The technique increases circulating tumor DNA by 1.6- to 5.6-fold, providing valuable genetic information for treatment decisions.
A study comparing PI-RADS 2.0 and 2.1 found no significant differences in upgrade (29% vs. 22%) or downgrade (19% vs. 21%) rates from targeted biopsy to radical prostatectomy, suggesting no improvement in prostate cancer grade assessment with the latest PI-RADS update.
Breast milk from breast cancer patients contains tumour DNA that can be detected through liquid biopsy, offering a potential new tool for early diagnosis. The study found that ctDNA was detectable in 13 of 15 breast milk samples collected from breast cancer patients, outperforming detection in blood samples.
Researchers have demonstrated the effectiveness of five noninvasive tests for liver disease, which could revolutionize diagnosis and treatment. These tests use disease biomarkers and may enable breakthrough discoveries in developing new treatments for patients with liver disease.
Researchers from Helmholtz Munich and TU Dresden develop AI-powered biomarker detection that outperforms previous approaches. The algorithm achieves high sensitivity on resection tissue samples and shows promise as a pre-screening tool for biopsy tissue.
A novel liquid biopsy technology developed by UCSC Assistant Professor Daniel Kim's lab leverages RNA 'dark matter' to enhance cancer diagnosis. The test detects both protein-coding and repetitive noncoding RNAs in the blood, showing improved sensitivity for early-stage cancer detection.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
A study found that PSMA PET/CT can accurately diagnose advanced prostate cancer in elderly patients without the need for a biopsy. The procedure reduced the number of biopsies and associated complications, while providing clinical suspicion-based staging data.
Researchers at Sylvester Comprehensive Cancer Center are working on a new urine test to detect prostate cancer, reducing the need for invasive biopsies. They will use exosomes, small extracellular vesicles, as a promising new biomarker and collaborate with Exosome Diagnostics.
Researchers demonstrate the potential of optical imaging for safely measuring vocal fold elasticity and pliability. The study found good agreement between Brillouin microspectroscopy results and conventional elasticity measurements.
A radiomic-based model using T2-weighted MRI data achieved high accuracy in diagnosing pediatric Crohn disease, outperforming expert radiologists. The model was ensembled with clinical data to further improve performance.
A team led by CHLA's Dr. Jesse Berry is conducting an international liquid biopsy retinoblastoma study to investigate the use of liquid biopsies for diagnosis and disease severity determination. The study will provide valuable genetic and chromosomal information, enabling oncologists to diagnose retinoblastoma at a molecular level.
Researchers have identified a biomarker called CXCL-9 that can be used to diagnose acute tubulointerstitial nephritis (AIN), a condition causing inflammation of the kidneys. The biomarker can be detected via a simple urine test, potentially reducing the need for kidney biopsies.
A UCLA research team has developed a new method called cfSort to accurately quantify tissue-derived cell-free DNA in liquid biopsies. The approach identifies unique methylation patterns for each tissue, enabling accurate diagnosis and monitoring of diseases.
Researchers developed a bio-sensing technology that measures PD1 ligand functionality to predict patient response to anti-PD1 therapy. This technology enables accurate prediction of patient response and tailoring treatments accordingly, improving cancer patients' lives.
A multicenter study found that deep learning-based computer-aided diagnosis significantly improved radiologists' diagnostic performance for breast lesion classification on ultrasound. The use of CAD resulted in a 6.0% upgrade of BI-RADS category 3 assessments to category 4A, with 16.7% being malignant.
A new liquid biopsy approach, ACT-Discover, shows improved sensitivity in detecting tumor DNA in blood for pancreatic cancer patients. The technique analyzes genomic and molecular characteristics over time to advance insights into disease evolution.
A study of 5302 patients found no significant difference in bleeding events between those temporarily discontinuing and maintaining antithrombotic therapy during image-guided breast biopsies. The findings support the safety of continuing antithrombotic therapy, but counsel patients on bruising risk.
Researchers review current treatment updates for systemic light chain (AL) amyloidosis, highlighting the need for early diagnosis and effective maintenance therapy. The article discusses the relationship between AL amyloidosis and monoclonal gammopathy of undetermined significance (MGUS), emphasizing the importance of regular monitoring.
Researchers discuss the importance of biomarkers in breast lump management, enabling patients to make informed decisions between proactive treatment and watchful waiting. The development of biomarkers could provide personalized risk assessments and guide treatment strategies for women with breast lumps.
Researchers at ETH Zurich have developed a new method called pharmacoscopy to test treatment options for multiple myeloma patients. This high-throughput screening platform analyzes the reactions of cancer cells to various treatments, offering personalized therapeutic strategies.
A study presented at the ARRS Annual Meeting reveals institutional variability in projection order and image acquisition timing for CEM protocol. Earlier-obtained recombined imaging is significantly preferred for cancer lesion characterization, with a trend towards prioritizing imaging the side of pathology.
A retrospective study found that elevated CA 19-9 and CEA levels were associated with worsened outcomes in duodenal adenocarcinoma patients. The study, which included 68 patients, suggests that these tumor markers may show promise as prognostic tools for this rare malignancy.
A team of scientists created a new, fast, and precise method for analyzing cells in tissue samples from cancer patients without the need for a trained pathologist. The method uses artificial intelligence to evaluate data produced by a technique called real-time deformability cytometry.